DarioHealth Corp. announced two new clinical studies presented at the 17thInternational Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 ? 9 in Florence, Italy.

Examining evolving standards for metabolic health: Improving outcomes with or without medication: The introduction of GLP-1s as an effective tool for both weight loss and diabetes management is evolving the standards of care for metabolic health conditions.  Dario's cardiometabolic solution integrates digital tools, connected devices and intelligent technologies to deliver a personalized and integrated experience to help drive better outcomes through effective behavior change. Members can utilize the Dario solution with or without a GLP-1 medication and receive support tailored to their unique need. To better understand the impact of the Dario solution on the populations eligible for a GLP-1, Dario is conducting a series of studies looking at the related clinical outcomes of those members taking a GLP-1 and those without the medication.

The first study presented at ATTD analyzed the data of members engaged in Dario's cardiometabolic solution to manage pre-diabetes, a condition that requires weight loss and regulation of A1c. The study looked at the data of 6,963 members living with pre-diabetes who used Dario's smart blood glucose meter alongside weight tracking to track their clinical measurements and engage in digital activities such as meal tagging. Results included a 6.38% reduction in weight for members with a baseline BMI of 30 and above and an overall reduction in blood glucose levels, with average blood glucose levels remaining below 140 mg/dL for one year.

Notably, users who consistently engaged in meal tagging activities, with an average frequency exceeding five times per month, experienced statistically significant and stronger reductions in average weight. The results are significant for people living with pre-diabetes, showing the self-management of pre-diabetes with a single digital platform can drive the behavior change necessary to reduce the risk of Type 2 diabetes. A second Dario study presented at ATTD evaluated the effectiveness of Dario's digital health solution as a means to improve flu vaccine awareness and rates.

To conduct the analysis, a group of 64,904 Dario members with Type 1 or Type 2 diabetes were randomly assigned to one of three test groups assigned to receive flu vaccine nudge intervention messaging: a previously published intervention of one message a month; an adapted intervention with revised cadence of 2 ? 3 messages a month based on Dario platform user experience; and a group with no intervention (Control). Members who received messages as part of the first two test groups, both the published intervention group and the adapted intervention group receiving more frequent communications, showed a higher self-reported rate of flu vaccinations versus the control group.

Those members in the adapted intervention group demonstrated a higher self-reported follow-through vaccination rate. This group also reported significantly greater awareness of the risks of influenza and greater recollection of educational content. Overall, the study signals that digital health platforms with an established relationship in existing member bases can play an effective role in supporting flu vaccination campaigns and outcomes.